We conducted a randomized , placebo-controlled trial to assess daily treatment with oral tenofovir disoproxil fumarate ( TDF ) , oral tenofovir-emtricitabine ( TDF-FTC ) , or 1 % tenofovir ( TFV ) vaginal gel as preexposure prophylaxis against HIV-1 infection in women in South Africa , Uganda , and Zimbabwe .